The emergence of combination therapy using ICIs and anti-VEGF shows significant advancement in stimulating antitumor immune response and disrupting the tumor microenvironment, targeting both the immune checkpoint pathway and angiogenesis for HCC. Here, VEGFA is linked to hepatocellular carcinoma.